Tracon Pharmaceuticals has agreed to pay Micromet more than $100 million in milestones for the successful development of its D93 antibody for cancer. Micromet filed an IND for D93 last year and a Phase I trial is planned for the second half of this year.
"D93 is a first-in-class humanized antibody that will be developed for the treatment of a variety of cancers to complement other currently available therapies," said Charles P. Theuer MD, PhD, president and CEO of TRACON Pharmaceuticals. Micromet was a 2004 Fierce 15 company
- check out the release on the deal